Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus
Conclusions
We demonstrated the significance of IL-4 in reversing B cell anergy and established the scientific rationale to treat SLE via blocking IL-4 signalling, also providing diagnostic and prognostic biomarkers to identify patients who are most likely going to benefit from such treatments. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Liu, Y., Zhang, Z., Kang, Z., Zhou, X.-j., Liu, S., Guo, S., Jin, Q., Li, T., Zhou, L., Wu, X., Wang, Y.-n., Lu, L., He, Y., Li, F., Zhang, H., Liu, Y., Xu, H. Tags: ARD, Systemic Lupus erythematosus Source Type: research
Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis
Conclusions
Individuals with AS have different immunological and genetic profiles, as determined by evaluating the exosomes of these patients. The inhibitory effect of exosomes on Treg in AS suggests a mechanism contributing to chronically activated T cells in this disease. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Tavasolian, F., Lively, S., Pastrello, C., Tang, M., Lim, M., Pacheco, A., Qaiyum, Z., Yau, E., Baskurt, Z., Jurisica, I., Kapoor, M., Inman, R. D. Tags: ARD, Spondyloarthritis Source Type: research
New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function
Conclusions
Collectively, our preclinical and in vitro clinical evidence indicates high efficacy and therapeutic potency of Ab-IPL-IL-17, supporting the rationale for large-scale clinical evaluation of Ab-IPL-IL-17 in patients with IMIDs. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Saviano, A., Manosour, A. A., Raucci, F., Merlino, F., Marigliano, N., Schettino, A., Wahid, M., Begum, J., Filer, A., Manning, J. E., Casillo, G. M., Piccolo, M., Ferraro, M. G., Marzano, S., Russomanno, P., Bellavita, R., Irace, C., Amato, J., Alfaifi, Tags: Open access, ARD, Spondyloarthritis Source Type: research
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Conclusions
The efficacy of BKZ in bDMARD-naïve patients with PsA was sustained from Week 16 to Week 52. BKZ was well tolerated with no new safety signals observed.
Trial registration number
NCT03895203. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Ritchlin, C. T., Coates, L. C., McInnes, I. B., Mease, P. J., Merola, J. F., Tanaka, Y., Asahina, A., Gossec, L., Gottlieb, A. B., Warren, R. B., Ink, B., Bajracharya, R., Shende, V., Coarse, J., Landewe, R. B. Tags: Open access, ARD, Psoriatic arthritis Source Type: research
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Conclusion
In patients with RA in remission for more than 1 year while using TNFi, an increase in flare rate was reported in those who tapered TNFi to discontinuation. However, most regained remission after reinstatement of full-dose treatment.
Trial registration numbers
EudraCT: 2012-005275-14 and clinicaltrials.gov: NCT01881308. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Lillegraven, S., Paulshus Sundlisaeter, N., Aga, A.-B., Sexton, J., Olsen, I. C., Lexberg, A. S., Madland, T. M., Fremstad, H., Hoili, C. A., Bakland, G., Spada, C., Haukeland, H., Hansen, I. M., Moholt, E., Uhlig, T., Solomon, D. H., van der Heijde, D., Tags: Open access, ARD Lay summaries, ARD, Rheumatoid arthritis Source Type: research
Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study
Conclusions
GC was associated with a duration and dose-dependent increased risk of MACE in patients with RA. Very low dose prednisolone (<5 mg daily) did not appear to confer excessive CV risk. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: So, H., Lam, T. O., Meng, H., Lam, S. H. M., Tam, L.-S. Tags: Editor's choice, ARD Lay summaries, ARD, Rheumatoid arthritis Source Type: research
Nanna Svartz (1890-1986) and the discovery of sulfasalazine
On 17 December 1937, the King of Sweden, Gustaf V, signed a document appointing Nanna Svartz (1890–1986) as full professor of medicine at Karolinska Hospital in Stockholm. This was a remarkable event at the time. No woman had previously been trusted with a chair in any of the three universities in Sweden. She had seven male competitors, and critical voices claimed that a woman in menopause age would be unable to master such a demanding post. There existed only four chairs of medicine in Sweden. Full professorships were highly sought after and almost a requirement for survival in academic medicine. In her autobiograph...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Wollheim, F. A. Tags: ARD Heroes and pillars of rheumatology Source Type: research
T follicular helper cells and T peripheral helper cells in rheumatic and musculoskeletal diseases
Recent technological progress has greatly advanced our understanding of human immunology. In particular, the discovery of human T follicular helper (Tfh) and T peripheral helper (Tph) cells has significantly advanced our understanding of human adaptive immune system. Tfh and Tph cells share similar molecular characteristics and both play critical roles in B cell differentiation and maturation. However, they differ in their functional properties, such as chemokine receptor expression and cytokine production. As a result, Tfh cells are mainly involved in B cell differentiation and maturation in germinal centres of secondary ...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Akiyama, M., Alshehri, W., Yoshimoto, K., Kaneko, Y. Tags: ARD Reviews Source Type: research
Decoding B cell receptors in autoimmune diseases
Numerous autoimmune diseases are characterised by the presence of autoantibodies, some of which help in diagnosis, others of which contribute to pathogenesis. In many of these diseases, B cell targeted therapies are of benefit. This has led to intensive exploration of B cell subset and mechanisms of B cell activation, yet studies of B cell repertoire in health and disease are still in their infancy. In this issue of the journal, Ota et al report on B cell receptor (BCR) heavy chain sequences from 595 donors, from individuals with autoimmune diseases and healthy donors.1 The BCR sequences were mapped from bulk RNA-sequencin...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Atisha-Fregoso, Y., Diamond, B. Tags: ARD Editorials Source Type: research
Correction: Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis
Kugler M, Dellinger M, Kartnig F, et al. Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis. Ann Rheum Dis 2023;82:1142-52. doi:10.1136/ard-2022–2 23 396
The following funding information was omitted in error from the published article:
This work was supported by the Innovative Medicines Initiative Joint Undertaking under grant agreement no 777 357 (RTCure) and by Oesterreichische Nationalbank Jubilaeumsfonds (grant agreement no 17558). (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Tags: ARD Correction Source Type: research
Correction: Points to consider: EULAR-UEMS standards for the training of European rheumatologists
Alunno A, Avcin T, Haines C, et al. Points to consider: EULAR–UEMS standards for the training of European rheumatologists. Ann Rheum Dis 2023;82:1107–13. doi: 10.1136/ard-2023-223941 This is the correct version of the author affiliations. The incorrect version appeared in the August 2023 print issue. Alessia Alunno1, Tadej Avčin2, Catherine Haines3, Sofia Ramiro4,5, Francisca Sivera6,7, Sara Badreh8, Xenofon Baraliakos9, Johannes WJ Bijlsma10, Frank Buttgereit11, Kaushik Chaudhuri12, Jose Antonio P da Silva13,14, Jean Dudler15, Ricardo J O Ferreira16,17,18, Tania E Gudu19, Eric Hachulla20, Mette Holland-...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Tags: ARD Correction Source Type: research
Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
The SARS-CoV-2 disease 2019 (COVID-19) pandemic deeply affected all Brazilian regions. Brazil has seen approximately 12 million cases of COVID-19 and over 294 042 deaths to date (21 March 2021) (https://COVID-19.saude.gov.br/), and the end of the pandemic cannot yet be predicted. The COVID-19 pandemic scenario represents a source of concern for the management of patients with chronic diseases and comorbidities, including autoimmune diseases, such as systemic lupus erythematosus (SLE).1 The new viral infection caused by SARS-CoV-2 seems to lead to the onset or exacerbation of autoimmune diseases in genetically predisposed p...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Martelli Junior, H., Marques, N. P., Marques, N. C. T., Gomes de Lucena, E., Martelli, D. R. B., Oliveira, E. A. Tags: ARD, COVID-19 Correspondence Source Type: research
Correspondence on 'Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
We read with interest the article by Bower et al detailing the impact of the COVID-19 pandemic on mortality and morbidity among patients with rheumatic diseases (RDs).1 Though Bower et al reported that the risks of severe COVID-19-related outcomes among patients with RD, such as increased risk of hospitalisation and death, were largely proportionate to those in the general population and explained by comorbidities, risks of severe COVID-19-related outcomes were still increased among patients with RD.1 Indeed, in a separate cohort of inpatients with systemic lupus erythematosus and concomitant SARS-CoV-2 infection, almost o...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Wee, L. E., Conceicao, E. P., Tan, J. Y., Thumboo, J., Venkatachalam, I. Tags: ARD, COVID-19 Correspondence Source Type: research
Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
We have read with great interest the work of Anna Molto et al studying on comparing the benefits of TICOSPA (a tight control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA)) trial with those of usual care (UC).1 They concluded that TC/T2T approach was not significantly superior to UC for the primary outcome, while it might be beneficial in axSpA and had a favourable outcome from a societal health economic perspective. However, we believe that some concerns should be discussed in this important study. First of all, although the primary endpoint Assessmnet of SpondyloArthritis international Society Healt...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Authors: Wang, W., Lee, Y.-H., Wei, J. C. C. Tags: ARD Correspondence Source Type: research
Correction: Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Hoisnard L, Pina Vegas L, Dray-Spira R, et al. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis 2023;82:182-8. doi:10.1136/ard-2022-222824 In discussion on page 187, the following sentence does not contain the final results: "Our results for subgroups of patients with at least one cardiovascular risk who were 50 years old or older and 65 years old or older were not significant for risk of both MACEs and VTEs with a JAKi compared with the TNFi adalimumab: HRw 2.1 (0.6 to 7.8) and ...
Source: Annals of the Rheumatic Diseases - October 12, 2023 Category: Rheumatology Tags: ARD Correction Source Type: research
